StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Titan Pharmaceuticals stock opened at $3.86 on Monday. Titan Pharmaceuticals has a 1-year low of $3.51 and a 1-year high of $14.80. The firm’s fifty day simple moving average is $4.50 and its 200-day simple moving average is $5.53.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.